Journal Information

On this page: Aims & scope | Subject categories | Journal metrics | Indexing | eISSN

Aims and scope

BJC Reports is a general oncology journal that publishes across the spectrum of cancer research. A partner journal to the BJC, one of the most cited general oncology journals, BJC Reports is an open access journal focused on rapid publication and global reach.

With the intention of providing a platform for the dissemination of basic, translational and clinical research, BJC Reports covers topics including, but not limited to, data science, artificial intelligence/machine learning applications in cancer,  tumourigenesis and underlying cancer biology, screening and risk, early detection and diagnosis, prognosis and cancer management, as well as new therapeutic approaches. BJC Reports also welcomes negative studies, and all cancer types, including benign tumours, will be considered for publication. 

BJC Reports publishes Research articles, Reviews, Perspectives, Consensus Articles, Editorials, Comments, Guidelines, Protocols, Conference Proceedings, Correspondence, and Case Reports, with the intention of providing a varied platform through which authors may communicate their research. The journal also publishes relevant guest-edited topical collections.

Submit your next manuscript to BJC Reports and benefit from:

  • Rapid decision and publication times.
  • High exposure and article visibility via nature.com.
  • Free OA support service available to authors.
  • Share your article through SharedIt: Springer Nature’s content-sharing initiative allowing authors and subscribers to share links to view-only, full-text articles from this journal
  • Publishing across the spectrum of cancer research.
  • A partner journal to the British Journal of Cancer.
  • High visibility for your work with open access.

Subject categories

BJC Reports publishes across the following five subject categories, which closely match those of our partner journal, the British Journal of Cancer:

  • Cellular and Molecular Biology
  • Clinical Studies
  • Epidemiology
  • Genetics, Genomics, and Molecular Diagnostics
  • Translational Therapeutics

Cellular and Molecular Biology
The Cellular and Molecular Biology subject category considers studies that provide novel insight into basic cellular and molecular mechanisms of cancer, but are not biomarker, methodology, or pathology focused. Studies considered for this category will generally go beyond in vitro and/or in silico evaluation of basic cellular and molecular mechanisms of cancer, and usually include the use of appropriate in vivo model systems. Findings of studies considered for this category should be clinically and/or therapeutically applicable.

Epidemiology
The Epidemiology subject category focuses on prevention, early detection, and factors that influence the risk and prognosis of cancer.

Genetics, Genomics, and Molecular Diagnostics
This subject category covers the use of genetic epidemiology and bioinformatics, together with molecular and cell biology, to identify and characterise the genetic and epigenetic factors underlying tumour development and progression. We are interested in papers which focus on the mechanistic consequences of genetic variance, and adequately powered studies of how genetic and epigenetic variation impacts patient risk and outcome phenotypes, in particular where these point to new clinical approaches. Wherever possible, bioinformatics analyses should be supported by experimental results. The subject category also considers molecular diagnostics studies that examine genomic, transcriptomic, epigenomic, and proteomic biomarkers in the context of cancer diagnosis, staging, prognosis, therapeutic prediction, and radiographic and pathologic characteristics. We are particularly interested in papers that explore novel or evolving biomarkers with direct clinical applicability in cancer care.

Translational Therapeutics
Translational Therapeutics is dedicated to scientific work that has possible direct applicability in clinical uses or opens new avenues for treatments. The type of manuscript ranges from basic research to early informative clinical trials with extensive concomitant biomaterial analyses. Translational concepts include new computational or wet lab Technologies as well.

Journal Metrics

Article metrics such as number of downloads, citations and online attention are available from each article page, and provide an overview of the attention received by a paper.

Usage 2023

  • Downloads: 13,305
  • Altmetric mentions: 138

More about our metrics

Indexing

All articles published in BJC Reports are deposited in digital archives around the world to guarantee long-term digital preservation. We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in BJC Reports will be available in their databases when appropriate.

eISSN

The electronic international standard serial number (eISSN) for BJC Reports is 2731-9377.